-
EP3698850
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3698850
| EP3698850 - TUMOR-INFILTRATING LYMPHOCYTES FOR ADOPTIVE CELL THERAPY [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 05.08.2022 Database last updated on 09.04.2026 | |
| Former | Request for examination was made Status updated on 24.07.2020 | Most recent event Tooltip | 28.03.2025 | New entry: Renewal fee paid | Applicant(s) | For all designated states H. Lee Moffitt Cancer Center And Research Institute, Inc. 12902 Magnolia Drive Tampa, FL 33612 / US | For all designated states University of South Florida 3802 Spectrum Blvd., Suite 100 Tampa, FL 33612 / US | [2020/35] | Inventor(s) | 01 /
SARNAIK, Amod A. 5001 Waterkey Way Tampa, FL 33647 / US | 02 /
PILON-THOMAS, Shari 4008 Barwood Court Tampa, FL 33624 / US | 03 /
MCLAUGHLIN, Mark 3419 W. San Luis Street Tampa, FL 33629 / US | 04 /
LIU, Hao 8182 Stone View Drive Tampa, FL 33647 / US | [2020/35] | Representative(s) | Creek, Isobel Clare The IP Asset Partnership Limited Prama House 267 Banbury Road Oxford OX2 7HT / GB | [N/P] |
| Former [2020/35] | Icely, Dominic Michael The IP Asset Partnership Limited Prama House 267 Banbury Road Oxford OX2 7HT / GB | Application number, filing date | 19220121.8 | 20.03.2015 | [2020/35] | Priority number, date | US201461955970P | 20.03.2014 Original published format: US 201461955970 P | US201461973002P | 31.03.2014 Original published format: US 201461973002 P | [2020/35] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3698850 | Date: | 26.08.2020 | Language: | EN | [2020/35] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 09.06.2020 | Classification | IPC: | A61P35/00, C07K14/705, C12N5/0783 | [2020/35] | CPC: |
C12N5/0636 (EP,KR,US);
A61K35/12 (US);
A61K40/11 (EP,KR,US);
A61K40/4271 (EP,US);
A61P1/00 (EP);
A61P15/00 (EP);
A61P17/00 (EP);
A61P35/00 (EP,KR);
A61P35/04 (EP,KR);
G01N33/505 (US);
A61K2239/57 (EP,KR,US);
C12N2501/05 (EP,US);
C12N2501/056 (EP,KR,US);
C12N2501/2302 (EP,KR,US);
C12N2501/50 (US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/35] | Title | German: | TUMORINFILTRIERENDE LYMPHOZYTEN ZUR ADOPTIVEN ZELLTHERAPIE | [2020/35] | English: | TUMOR-INFILTRATING LYMPHOCYTES FOR ADOPTIVE CELL THERAPY | [2020/35] | French: | LYMPHOCYTES INFILTRANT LES TUMEURS POUR THÉRAPIE CELLULAIRE ADOPTIVE | [2020/35] | Examination procedure | 30.12.2019 | Examination requested [2020/35] | 25.02.2021 | Amendment by applicant (claims and/or description) | 17.10.2022 | Despatch of a communication from the examining division (Time limit: M04) | 16.02.2023 | Reply to a communication from the examining division | 05.08.2024 | Despatch of a communication from the examining division (Time limit: M06) | 04.02.2025 | Reply to a communication from the examining division | Parent application(s) Tooltip | EP15765854.3 / EP3119477 | Fees paid | Renewal fee | 30.12.2019 | Renewal fee patent year 03 | 30.12.2019 | Renewal fee patent year 04 | 30.12.2019 | Renewal fee patent year 05 | 12.03.2020 | Renewal fee patent year 06 | 12.03.2021 | Renewal fee patent year 07 | 20.03.2022 | Renewal fee patent year 08 | 14.02.2023 | Renewal fee patent year 09 | 13.03.2024 | Renewal fee patent year 10 | 27.03.2025 | Renewal fee patent year 11 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A] CN103520198 (PENG GUANGYONG et al.) | [X] DUDLEY MARK E ET AL: "Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma", JOURNAL OF CLINICAL ONCOLOGY,, vol. 23, no. 10, 1 April 2005 (2005-04-01), pages 2346 - 2357, XP002433186, ISSN: 0732-183X, DOI: 10.1200/JCO.2005.00.240 DOI: http://dx.doi.org/10.1200/JCO.2005.00.240 | [X] SHARI PILON-THOMAS ET AL: "Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma :", JOURNAL OF IMMUNOTHERAPY, vol. 35, no. 8, 1 October 2012 (2012-10-01), US, pages 615 - 620, XP055411327, ISSN: 1524-9557, DOI: 10.1097/CJI.0b013e31826e8f5f DOI: http://dx.doi.org/10.1097/CJI.0b013e31826e8f5f | [X] GUANGYONG PENG ET AL: "Tumor-Infiltrating [gamma][delta] T Cells Suppress T and Dendritic Cell Function via Mechanisms Controlled by a Unique Toll-like Receptor Signaling Pathway", IMMUNITY., vol. 27, no. 2, 1 August 2007 (2007-08-01), US, pages 334 - 348, XP055300674, ISSN: 1074-7613, DOI: 10.1016/j.immuni.2007.05.020 DOI: http://dx.doi.org/10.1016/j.immuni.2007.05.020 | [Y] V. ANDREANI ET AL: "Activation of Toll-like Receptor 4 on Tumor Cells In vitro Inhibits Subsequent Tumor Growth In vivo", CANCER RESEARCH, vol. ovarian cancer inflitrating DCs treated with CD467, no. 21, 1 November 2007 (2007-11-01), US, pages 10519 - 10527, XP055411321, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-07-0079 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-07-0079 | [Y] MOHAMED LABIB SALEM ED - PISTOIA VITO: "Triggering of toll-like receptor signaling pathways in T cells contributes to the anti-tumor efficacy of T cell responses", IMMUNOLOGY LETTERS, ELSEVIER BV, NL, vol. 137, no. 1, 16 February 2011 (2011-02-16), pages 9 - 14, XP028193791, ISSN: 0165-2478, [retrieved on 20110223], DOI: 10.1016/J.IMLET.2011.02.019 DOI: http://dx.doi.org/10.1016/j.imlet.2011.02.019 | [Y] SALEM M L ET AL: "The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into naive recipient mice", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 27, no. 4, 22 January 2009 (2009-01-22), pages 549 - 557, XP025838785, ISSN: 0264-410X, [retrieved on 20081121], DOI: 10.1016/J.VACCINE.2008.11.013 DOI: http://dx.doi.org/10.1016/j.vaccine.2008.11.013 | [Y] JESSICA ANN CHACON ET AL: "Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8+ Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy", PLOS ONE, vol. 8, no. 4, 1 April 2013 (2013-04-01), pages e60031, XP055416340, DOI: 10.1371/journal.pone.0060031 DOI: http://dx.doi.org/10.1371/journal.pone.0060031 | [Y] GORTER A ET AL: "ENHANCEMENT OF THE LYTIC ACTIVITY OF CLONED HUMAN CD8 TUMOUR-INFILTRATING LYMPHOCYTES BY BISPECIFIC MONOCLONAL ANTIBODIES", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 87, no. 1, 1 January 1992 (1992-01-01), pages 111 - 116, XP008042889, ISSN: 0009-9104 | [A] S. KACZANOWSKA ET AL: "TLR agonists: our best frenemy in cancer immunotherapy", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 93, no. 6, 8 March 2013 (2013-03-08), pages 847 - 863, XP055129728, ISSN: 0741-5400, DOI: 10.1189/jlb.1012501 DOI: http://dx.doi.org/10.1189/jlb.1012501 | [A] DUTHIE M S ET AL: "Use of defined TLR ligands as adjuvants within human vaccines", IMMUNOLOGICAL REVIEWS, WILEY-BLACKWELL PUBLISHING, INC, US, vol. 239, no. 1, 1 January 2011 (2011-01-01), pages 178 - 196, XP009155275, ISSN: 0105-2896, DOI: 10.1111/J.1600-065X.2010.00978.X DOI: http://dx.doi.org/10.1111/j.1600-065X.2010.00978.x | [A] C. M. PAULOS ET AL: "Toll-like Receptors in Tumor Immunotherapy", CLINICAL CANCER RESEARCH, vol. 13, no. 18, 15 September 2007 (2007-09-15), US, pages 5280 - 5289, XP055416343, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-07-1378 DOI: http://dx.doi.org/10.1158/1078-0432.CCR-07-1378 | [A] M. SAINT-JEAN ET AL: "P003. TLR7 and TLR8 expression by melanoma cells correlates with a better relapse-free survival for stage III melanoma patients :", MELANOMA RESEARCH, vol. 21, 1 June 2011 (2011-06-01), US, pages e18, XP055694535, ISSN: 0960-8931, DOI: 10.1097/01.cmr.0000399464.40495.a6 DOI: http://dx.doi.org/10.1097/01.cmr.0000399464.40495.a6 | [A] "Cancer Immunotherapy", 1 January 2007, ELSEVIER, ISBN: 978-0-12-372551-6, article RONG-FU WANG: "Regulatory T cells in Tumor Immunity: Role of Toll-Like Receptors", pages: 277 - 287, XP055694536, DOI: 10.1016/B978-012372551-6/50079-1 DOI: http://dx.doi.org/10.1016/B978-012372551-6/50079-1 | by applicant | US2011052530 | WO2013192628 | US5811515 | US8592377 | US8324428 | US8198405 | US7786072 | US7723469 | US7192713 | US5631280 | US5612895 | US5579250 | ROSENBERG SA ET AL., CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 17, no. 13, 2011, pages 4550 - 7 | PILON-THOMAS S ET AL., J IMMUNOTHER., vol. 35, no. 8, 2012, pages 615 - 20 |